Anna B. Halpern, MD

Physician
Seattle Cancer Care Alliance
Assistant Professor, Hematology
University of Washington School of Medicine
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Specialty:
Medical Oncology
“One of the most rewarding parts of my job is getting to know you and your family so we can work together in a close partnership. I believe we have much to learn from each other.”
— Dr. Halpern
Why did you decide to go into cancer care?

I enjoy the opportunity to develop deep, long-term relationships with you and your family as well as the exciting pace of the oncology field. Oncology is moving so fast, and we’re continually improving the treatment options we can offer you. There’s so much innovation in the way researchers approach the disease, from personalized regimens that target each cancer’s mutations to therapies that harness the body’s immune system. It inspires me as a clinician and as a researcher.

Anna_Halpern_Secondary.jpg
What is your approach to caring for a patient?

I work with you to design and implement a personalized plan of cancer care that balances your and your family’s needs, the characteristics of your disease and the leading-edge science and clinical trials offered at SCCA.

Provider background

Specialty: Medical Oncology

Area of clinical practice

Hematologic malignancies

Leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use large databases to study systems issues on a broader scale, such as risk factors for toxicities from treatment.

Hematologist A physician who specializes in diseases of the blood and blood-forming tissues.

Diseases treated

Education, experience and certifications
Undergraduate Degree
Brown University
Medical Degree
Warren Alpert Medical School of Brown University
Residency
University of Chicago
Fellowship
Fred Hutch and University of Washington
Board Certification
Medical Oncology, 2016; Hematology, 2016; Internal Medicine, 2012, American Board of Internal Medicine
Other
Teaching Appointment, University of Chicago Medical Center
Languages
English
Awards
Young Investigator Award, American Society of Clinical Oncology, 2016

Stories

Innovation in oncology care management: exploring a novel treatment model for outpatient leukemia induction chemotherapy
Innovation in oncology care management: exploring a novel treatment model for outpatient leukemia induction chemotherapy

The initiation of intense induction chemotherapy for patients with Acute Myeloid Leukemia (AML) has traditionally required long inpatient admissions. These hospitalizations – lasting four to five weeks on average – have been accepted as the standard of care given the need for management of treatment-related cytopenia and the associated infectious and bleeding risks. 

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04279847
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Complete title
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Study ID:
NCT02649790
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Complete title
A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS
Study ID:
NCT04551066
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Complete title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Press

SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Patient care coordinator
Patient care coordinator
Your patient care coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers